Canada's NeuPath Health Q2 revenue falls despite record patient visits

NeuPath Health

13/08/2026 12:38

Overview
Canada pain treatment clinic operator's Q2 revenue declined 2% yr/yr
Adjusted EBITDA for Q2 fell 23% yr/yr, impacted by prior-year one-time payment
Company says organic growth driven by record patient visits and improved capacity utilization

Outlook
Company did not provide specific guidance for future quarters or the full year

Result Drivers
RECORD PATIENT VISITS - Co said organic revenue growth was driven by record patient visits
CAPACITY UTILIZATION - Co attributed improved clinic revenue to increased physical capacity utilization in its facilities
ARTHROSAMID AND FLUOROSCOPY - Continued growth from Arthrosamid and fluoroscopy revenues contributed to clinic revenue

Company press release: ID:nBw70v4MMa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Miss*
C$23.20 mln
C$23.35 mln (2 Analysts)
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for NeuPath Health Inc is C$0.77, about 19.5% above its August 12 closing price of C$0.64
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads
Aug 12 - Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Aug 13 - Aveanna Healthcare Q2 revenue beats on broad-based growth
Aug 10 - Surgery Partners Q2 revenue beats on growth in same-facility segment

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)